Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 1:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 402 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Twice Weekly Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

NCT04772885
View directory record Official record
Conditions
Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
Interventions
KT-474/Placebo, KT-474
Drug
Lead sponsor
Kymera Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
14
States / cities
Phoenix, Arizona • Sun City West, Arizona • Boynton Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2022 · Synced Sep 11, 2026, 1:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Culturally Adapted Mobile Treatment of Chronic Pain in Adolescent Survivors of Pediatric Cancer

NCT05746429
View directory record Official record
Conditions
Bone Sarcoma, Childhood Cancer
Interventions
Cognitive Behavior Therapy, Transcranial Direct Current Stimulation, Placebo Administration, Questionnaire Administration, Interview
Behavioral · Device · Drug + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
10 Years and older
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 11, 2026, 1:45 PM EDT
Enrolling by invitation Not applicable Interventional

HIFEM Technology for Post-Radical Prostatectomy and Post-Holmium Laser Prostate Surgery

NCT06803602
View directory record Official record
Conditions
Holmium Laser Prostate Surgery, Radical Prostatectomy
Interventions
EMSELLA®, Sham Comparator Device
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
2,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 11, 2026, 1:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Effect of Exercise and Alagebrium on the Diastolic Function of the Heart

NCT01014572
View directory record Official record
Conditions
Ventricular Function
Interventions
Aerobic Exercise Training, Alagebrium (generic: ALT-711), Tai Chi and/or Yoga Training
Behavioral · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
65 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Sep 11, 2026, 1:45 PM EDT
Completed Phase 3 Interventional Results available

54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

NCT03039192
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Esketamine, Placebo, Standard of Care
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
17
States / cities
Birmingham, Alabama • Chandler, Arizona • Garden Grove, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 11, 2026, 1:45 PM EDT
Completed Phase 1Phase 2 Interventional

Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection

NCT00911963
View directory record Official record
Conditions
Hepatitis C
Interventions
VCH-222 or matching placebo, peginterferon alfa-2a, ribavirin
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Marietta, Georgia • Detroit, Michigan • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2014 · Synced Sep 11, 2026, 1:45 PM EDT
Completed Phase 2 Interventional Results available

A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients

NCT02640807
View directory record Official record
Conditions
Severe Sepsis With Septic Shock
Interventions
Interleukin-7, Placebo
Drug
Lead sponsor
Revimmune
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Sep 11, 2026, 1:45 PM EDT
Recruiting Phase 2 Interventional

Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

NCT07226661
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
SPN-821 2400 mg, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 11, 2026, 1:45 PM EDT
Completed Not applicable Interventional

Acupuncture in Treating Women With Stage I, Stage II, or Stage III Breast Cancer With Aromatase Inhibitor-Related Joint Pain

NCT01013337
View directory record Official record
Conditions
Breast Cancer, Recurrent Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
acupuncture therapy, sham intervention
Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Sep 11, 2026, 1:45 PM EDT
Terminated Phase 2 Interventional Results available

Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders

NCT01273064
View directory record Official record
Conditions
Hepatitis C
Interventions
CTS-1027, pegylated interferon, Ribavirin, Placebo
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
45
States / cities
Birmingham, Alabama • Coronado, California • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Sep 11, 2026, 1:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

CRT-Guanfacine for SPD

NCT02524899
View directory record Official record
Conditions
Schizotypal Personality Disorder, SPD
Interventions
Cognitive Remediation Therapy, Guanfacine, Placebo
Behavioral · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Sep 11, 2026, 1:45 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

NCT02422186
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (New Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
65 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
San Diego, California • New Haven, Connecticut • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 11, 2026, 1:45 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients

NCT01289782
View directory record Official record
Conditions
Hepatitis C
Interventions
Placebo, TMC435, Peginterferon alpha-2a (PegIFN alpha-2a), Ribavirin (RBV)
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
22
States / cities
Dothan, Alabama • Hoover, Alabama • Phoenix, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Sep 11, 2026, 1:45 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)

NCT02833350
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GDC-0853, Adalimumab, Folic Acid, MTX, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Anniston, Alabama • Glendale, Arizona • Covina, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Sep 11, 2026, 1:45 PM EDT
Completed Phase 2 Interventional

Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer

NCT01792050
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Docetaxel, Placebo, Indoximod, Paclitaxel
Drug · Other
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
28
States / cities
Gainesville, Florida • Tampa, Florida • Titusville, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Sep 11, 2026, 1:45 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C

NCT00336479
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Placebo
Drug · Other
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
36
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Sep 11, 2026, 1:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mind-body Treatments for Chronic Back Pain

NCT03294148
View directory record Official record
Conditions
Chronic Pain, Back Pain Lower Back Chronic, Back Pain, Low
Interventions
Open-Label Placebo Treatment for Chronic Back Pain, Psychotherapy Treatment for Chronic Back Pain
Other · Behavioral
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
21 Years to 70 Years
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Sep 11, 2026, 1:45 PM EDT
Enrolling by invitation Not applicable Interventional

Effects of Flavor Modification for Management of Radiation Induced Dysgeusia

NCT06311877
View directory record Official record
Conditions
Dysgeusia
Interventions
mBerry, No intervention
Dietary Supplement · Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Sep 11, 2026, 1:45 PM EDT
Completed Not applicable Interventional

Music Therapy to Prevent Hospital-acquired Delirium in Parkinson's Disease and Dementia With Lewy Bodies

NCT06063161
View directory record Official record
Conditions
Parkinson Disease, Dementia, Lewy Body, Delirium
Interventions
Music therapy intervention, Standard Care (in control arm)
Behavioral · Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
60 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Sep 11, 2026, 1:45 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

NCT05269355
View directory record Official record
Conditions
Leiomyosarcoma
Interventions
Unesbulin, Dacarbazine, Placebo
Drug · Other
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
23
States / cities
Duarte, California • Los Angeles, California • Santa Monica, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 11, 2026, 1:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet

NCT00585650
View directory record Official record
Conditions
Psoriasis
Interventions
Etanercept, Placebo injections
Biological · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Irvine, California • Winston-Salem, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced Sep 11, 2026, 1:45 PM EDT
Completed Phase 2 Interventional Results available

Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)

NCT01979016
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
Dupilumab, Placebo, Background treatment
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Chicago, Illinois • New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Sep 11, 2026, 1:45 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)

NCT00562497
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Prochymal®, Placebo, Corticosteroid
Drug · Other
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
45
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Sep 11, 2026, 1:45 PM EDT
Completed Not applicable Interventional Results available

Effect of Acupuncture on Patient Vulvodynia Outcomes

NCT03364127
View directory record Official record
Conditions
Vulvodynia, Vulvodynia, Generalized, Vulvar Vestibulitis
Interventions
Active Acupuncture, Placebo Acupuncture
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Sep 11, 2026, 1:45 PM EDT